Mucocutaneous Adverse Events in Patients With Cancer Treated with the Highly Selective RET Kinase Inhibitor Selpercatinib (LOXO-292) by Rachel E. Reingold, MD, Rose Parisi, MD, MBA, Guilherme Harada, MD, Andrea P. Moy, MD, George Dranitsaris, PhD, Jasmine H. Francis, MD, Julia Canestraro, OD, FAAO, Julia A. Lester, MPH, Lauren A. Kaplanis, RN, Dazhi Liu, PharmD, BCOP, Mario E. Lacouture, MD, Alexander Drilon, MD

Subjects: Get full text

Distinct Impacts of Clinicopathological and Mutational Profiles on Long-Term Survival and Recurrence in Medullary Thyroid Carcinoma by Moon Young Oh, Kyong Yeun Jung, Hoonsung Choi, Young Jun Chai, Sun Wook Cho, Su-jin Kim, Kyu Eun Lee, Eun-Jae Chung, Do Joon Park, Young Joo Park, Han-Kwang Yang

Subjects: Get full text

Medullary thyroid cancer in MEN2 pediatric/adolescent carriers of RET mutation: genotype/phenotype correlation and outcome in a retrospective series of 23 patients by Guenda Di Benedetto, Ignazio Barca, Laura De Gregorio, Claudia Scollo, Fiorenza Gianì, Federica Martorana, Marco Russo, Francesco Frasca, Gabriella Pellegriti, Gabriella Pellegriti, Giulia Sapuppo

Subjects: Get full text